Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
June 1, 2023 - FOSTER CITY, Calif. & SANTA MONICA, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.
At EHA, Gilead and Kite Oncology will present the latest data for investigational and approved blood cancer therapies including (all times CEST):
|
Tumor Type |
Abstract Title |
|
Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes |
|
|
Abstract #P699 Date: June 9 Time: 6:00p.m.–7:00p.m. CEST |
Magrolimab Alters the Tumor Microenvironment to Improve Bone Marrow Functions in Patients with Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) |
|
Abstract #P1003 Date: June 9 Time: 6:00p.m.–7:00p.m. CEST |
Ruxolitinib and Magrolimab increases Calreticulin in Myelofibrosis CD34+ Cells In Vitro: Proof of Concept for Combination Therapy
|
|
Abstract #PB1888 Online Publication Only |
Trial in Progress: Phase 1b/2 Study of Pivekimab Sunirine (PVEK, IMGN632) in Combination with Venetoclax/Azacitidine or Magrolimab for Patients with CD123-Positive Acute Myeloid Leukemia (AML) |
|
Abstract #PB2021 Online Publication Only |
Phase 2 Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab For Previously Untreated Subjects With Intermediate to Very High-risk Myelodysplastic Syndromes (MDS) |
|
Follicular Lymphoma |
|
|
Abstract #S223 Date: June 9 Time: 3:30p.m.–3:45p.m. CEST |
Real-world Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma |
|
Abstract #P1107 Date: June 9 Time: 6:00p.m.–7:00p.m. CEST |
ZUMA-22: A Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Patients with Relapsed or Refractory Follicular Lymphoma |
|
B-Cell Lymphoma |
|
|
Abstract #P1204 Date: June 9 Time: 6:00p.m.–7:00p.m. CEST |
Axicabtagene Ciloleucel Vein-to-Vein Time in Trial or Real-World Settings vs Other CAR T-cell Therapies for Relapsed/Refractory Large B-cell Lymphoma: A Systematic Literature Review and Meta-Analysis |
|
Abstract #PB2319 Online Publication Only |
ZUMA-23: A Global Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard of Care as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma |
|
Abstract #PB2346 Online Publication Only |
ZUMA-24: A Phase 2, Open-Label, Multicenter Study of Axicabtagene Ciloleucel in Patients with Relapse/Refractory Large B-Cell Lymphoma Given with Corticosteroids in the Outpatient Setting |
|
Abstract #PB2306 Online Publication Only |
Real-World First-Line Treatment and Outcomes Among Patients with High-Risk Diffuse Large B-Cell Lymphoma Treated with Standard Of Care |
|
Abstract #P1694 Date: June 9 Time: 6:00p.m.–7:00p.m. CEST |
Cost-Effectiveness of Axicabtagene Ciloleucel Vs. Tisagenlecleucel for the Treatment of Relapsed/Refractory large B-Cell Lymphoma: Updated s |